NO130400B - - Google Patents

Download PDF

Info

Publication number
NO130400B
NO130400B NO01242/70*[A NO124270A NO130400B NO 130400 B NO130400 B NO 130400B NO 124270 A NO124270 A NO 124270A NO 130400 B NO130400 B NO 130400B
Authority
NO
Norway
Prior art keywords
groups
isoxazolidine
grams
alkoxy
carbon atoms
Prior art date
Application number
NO01242/70*[A
Other languages
Norwegian (no)
Inventor
G Pifferi
Original Assignee
Lepetit Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lepetit Spa filed Critical Lepetit Spa
Publication of NO130400B publication Critical patent/NO130400B/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

Analogifremgangsmåte for fremstilling av Analogy method for the production of

terapeutisk aktive isoxazolidinderivater. therapeutically active isoxazolidine derivatives.

Foreliggende oppfinnelse angår en analogifremgangsmåte for fremstilling av nye isoxazolidinder ivater med d-en generelle formel: The present invention relates to an analogous process for the production of new isoxazolidine derivatives with d-a general formula:

hvor n er 0 eller 1, og F^, F?2 og R uavhengig representerer en hydroksy-, alkoksy- eller alkanoyloksygruppe med 1-4 karbonatomer, og hvor en av disse grupper kan være hydrogen. where n is 0 or 1, and F^, F^2 and R independently represent a hydroxy, alkoxy or alkanoyloxy group with 1-4 carbon atoms, and where one of these groups may be hydrogen.

De nye isoxåzolidinforbindelser virker på sentralnervesystemet, noe som indikeres ved deres effektivitet i stangklatringsunngåelsesprøver på rotter. De nye forbindelser er ganske enestående ved at de viser meget høy grad av aktivitet i nevnte prøver, mens de praktisk talt ikke har noen aktivitet nåi? de prøves for psyko-sedative og neuro-depressive effekter på mus. Denne egenskap sammen med meget lav toksitet, gjør at forbindelsene kan klassifiseres som selektivt psyko-aktive. Forbindelsene påvirker med andre ord angstoppførselen uten å svekke bevisstheten og uten muskeleffekter. Forbindelser som ligner de med den ovenfor angitte formel I er kjent fra US-patent 3-268.407, og som eksempel kan nevnes 3,4,5-trimetoksykanelsyre-amider hvilke virker på sentralnervesystemet som generiske depresjons-midler. The new isoxazolidine compounds act on the central nervous system, as indicated by their efficacy in rat pole-climbing avoidance tests. The new compounds are quite unique in that they show a very high degree of activity in said samples, while they have practically no activity in they are tested for psycho-sedative and neuro-depressive effects on mice. This property, together with very low toxicity, means that the compounds can be classified as selectively psychoactive. In other words, the compounds affect anxiety behavior without impairing consciousness and without muscle effects. Compounds similar to those with the formula I stated above are known from US patent 3-268,407, and as an example can be mentioned 3,4,5-trimethoxycinnamic acid amides which act on the central nervous system as generic depressants.

De nye forbindelser med formel I fremstilles ifølge oppfinnelsen ved at isoxazolidin enten i form av en fri base eller i form av syreaddisjonssalter med syrer, omsettes med et acylklorid The new compounds of formula I are prepared according to the invention by reacting isoxazolidine, either in the form of a free base or in the form of acid addition salts with acids, with an acyl chloride

med formel with formula

hvor n har samme betydning som angitt ovenfor, og R^, R^ og Rg uavhengig representerer alkoksy- eller alkanoyloksygrupper med 1-4 karbonatomer og hvor en av disse grupper kan være hydrogen,' i nærvær av en organisk nitrogenbase. Reaksjonen utføres i et organisk, vannfritt oppløsningsmiddel. Reaksjonen skjer ved temperaturer fra ca. 0°C til blandingens kokepunkt. Romtemperatur bør fortrinnsvis anvendes som den nedre grense. where n has the same meaning as stated above, and R^, R^ and Rg independently represent alkoxy or alkanoyloxy groups with 1-4 carbon atoms and where one of these groups may be hydrogen,' in the presence of an organic nitrogen base. The reaction is carried out in an organic, anhydrous solvent. The reaction takes place at temperatures from approx. 0°C to the boiling point of the mixture. Room temperature should preferably be used as the lower limit.

Mengden av reagenser er ikke kritisk, men man oppnår imidlertid de beste resultater når man bruker i alt vesentlig ekvi-molare mengder av isoxazolidinet og acylkloridet, mens den nitrogen-holdige organiske base tilsettes i mer eller mindre overskudd, fortrinnsvis i et forhold på 1,1 - 1,5 mol for hver ekvivalent av totalt tilstedeværende syre ved slutten av reaksjonen. Når en eller flere av substituentene i benzenringen i utgangsacylkloridet er alkanoyloksygrupper, så kan den fremstilte forbindelse eventuelt underkastes alkalisk hydrolyse, hvorved acylgruppene avspaltes og man oppnår det tilsvarende fénol. Dette trinn utføres ifølge vanlige fremgangsmåter, f.eks. ved å anvende et overskudd av- en base valgt fra gruppen bestående av ammoniumhydroksyd og alkalimetallhydroksyder 1 et vandig medium. Man har imidlertid også funnet.å kunne anvende organiske baser. The amount of reagents is not critical, but the best results are obtained when essentially equimolar amounts of the isoxazolidine and the acyl chloride are used, while the nitrogen-containing organic base is added in more or less excess, preferably in a ratio of 1, 1 - 1.5 mol for each equivalent of total acid present at the end of the reaction. When one or more of the substituents in the benzene ring in the starting acyl chloride are alkanoyloxy groups, the compound produced can optionally be subjected to alkaline hydrolysis, whereby the acyl groups are split off and the corresponding phenol is obtained. This step is carried out according to usual methods, e.g. by using an excess of a base selected from the group consisting of ammonium hydroxide and alkali metal hydroxides in an aqueous medium. However, it has also been found to be able to use organic bases.

Følgende eksempler illustrerer oppfinnelsen. The following examples illustrate the invention.

E ksempel 1 Example 1

2 - ( 5, 4, 5- trimetoksybenzoyl)- isoxazolidin 2-(5,4,5-trimethoxybenzoyl)-isoxazolidine

219,1 gram isoxazolidinhydroklorid oppløst i 3,5 liter metylenklorid ble langsomt tilsatt 620 ml trietylamin. Etter røring i 15 minutter ble 461 gram 3,4,5-trimetoksybenzoylklorid i 2,2 liter metylenklorid tilsatt i løpet av 40 minutter samtidig som tempera-turen ble holdt under 30°C. Reaksjonen ble først utført ved romtemperatur i 1 time under omrøring, og så under tilbakeløp i 2 timer til. Blandingen ble avkjølt, vasket med vann, 5%'s saltsyre, 5%'s natriumbikarbonat og endelig med vann til nøytralitet. Den organiske fase ble utskilt, tørket over natriumsulfat hvoretter oppløsnings-midlet ble fradestillert i vakuum. Resten som besto av 2-(3,4,5-trimetoksybenzoyD-isoxazolidin, ble utkrystallisert fra diisopropyl-eter. Utbytte 470 gram (88,0%), smeltepunkt 75-76°C. 219.1 grams of isoxazolidine hydrochloride dissolved in 3.5 liters of methylene chloride was slowly added to 620 ml of triethylamine. After stirring for 15 minutes, 461 grams of 3,4,5-trimethoxybenzoyl chloride in 2.2 liters of methylene chloride were added over the course of 40 minutes while keeping the temperature below 30°C. The reaction was first carried out at room temperature for 1 hour with stirring, and then under reflux for a further 2 hours. The mixture was cooled, washed with water, 5% hydrochloric acid, 5% sodium bicarbonate and finally with water to neutrality. The organic phase was separated, dried over sodium sulphate after which the solvent was distilled off in vacuo. The residue consisting of 2-(3,4,5-trimethoxybenzoyD-isoxazolidine) was crystallized from diisopropyl ether. Yield 470 grams (88.0%), mp 75-76°C.

Analyse: Analysis:

Eksem pel 2 2-( 3, 4- dimetoksybenzoyl)- isoxazolidin Ved samme fremgangsmåte som i eksempel 1, ble 2-(3,4-dimetoksybenzoyl)-isoxazolidin fremstilt ved å tilsette 6,1 gram 3,4-dimetoksybenzoylklorid oppløst i 107 ml metylenklorid til en suspensjon av 3,92 gram isoxazolidinhydroklorid og 10,2 ml trietylamin i 72 ml metylenklorid. Utbytte 4,4 gram (60,7%), smeltepunkt 87,5-88,5°€. Analyse: Example 2 2-(3,4-dimethoxybenzoyl)-isoxazolidine Using the same method as in example 1, 2-(3,4-dimethoxybenzoyl)-isoxazolidine was prepared by adding 6.1 grams of 3,4-dimethoxybenzoyl chloride dissolved in 107 ml of methylene chloride to a suspension of 3.92 grams of isoxazolidine hydrochloride and 10.2 ml of triethylamine in 72 ml of methylene chloride. Yield 4.4 grams (60.7%), melting point 87.5-88.5°€. Analysis:

Eksempel 3 Example 3

2 - ( 4- acetoksy-- 3, 5- dimetoksybenzoyl )- isoxazolidin 2 - ( 4- acetoxy-- 3, 5- dimethoxybenzoyl )- isoxazolidine

Denne forbindelse ble fremstilt ved samme fremgangsmåte som i eksempel r idet man anvendte 4,65 gram isoxazolidinhydroklorid, 14,3 ml trietylamin og 11 gram 4-acetoksy-3,-5-dimetoksybenzoylklorid. Utbytte 10 gram (81,7%), smeltepunkt 120-121°C. This compound was prepared by the same method as in example r, using 4.65 grams of isoxazolidine hydrochloride, 14.3 ml of triethylamine and 11 grams of 4-acetoxy-3,-5-dimethoxybenzoyl chloride. Yield 10 grams (81.7%), melting point 120-121°C.

Analyse: Analysis:

Eksempel 4 Example 4

2-( 4- acetoksy- 3, 5~ d imetoksyc innamoyl)- isoxazolidin 2-( 4- acetoxy- 3, 5~ dimethoxyc innamoyl)- isoxazolidine

Dette stoff ble fremstilt som beskrevet i eksempel 1, idet man anvendte 2,96 gram isoxazolidinhydroklorid, 9,1 ml trietylamin og 7,7 gram 4-acetoksy-3,5-dimetoksycinnamoylklorid. Utbytte 5,9 gram (68,0%), smeltepunkt 155-156°C. This substance was prepared as described in example 1, using 2.96 grams of isoxazolidine hydrochloride, 9.1 ml of triethylamine and 7.7 grams of 4-acetoxy-3,5-dimethoxycinnamoyl chloride. Yield 5.9 grams (68.0%), melting point 155-156°C.

Analyse: Analysis:

Eksempel 5 Example 5

2-( 3, 5~ dimetoksy- 4- hydroksybenzoyl)- isoxazolidin 2-(3,5~dimethoxy-4-hydroxybenzoyl)-isoxazolidine

4 .gram 2-(4-acetoksy-3,5-dimetoksybenzoyl)-isoxazolidin ble suspendert i '40 ml vann og 20 ml konsentrert ammoniakkoppløsning. Suspensjonen ble oppvarmet til ca. 80°C hvorved man fikk en full-stendig oppløsning av det faste stoff. Den varme væske ble filtrert og bragt til pH 7 med fortynnet saltsyre, deretter avkjølt på is i 2 timer. De dannede krystaller som bestod av 2-(3,5~dimetoksy-4-hydroksybenzoy1)-isoxazolidin, ble oppsamlet ved filtrering og tørket over fosforpentoksyd. Utbytte 2,68 gram (78,1%), smeltepunkt 75~ 76°C. Analyse: 4 grams of 2-(4-acetoxy-3,5-dimethoxybenzoyl)-isoxazolidine were suspended in 40 ml of water and 20 ml of concentrated ammonia solution. The suspension was heated to approx. 80°C whereby a complete dissolution of the solid was obtained. The hot liquid was filtered and brought to pH 7 with dilute hydrochloric acid, then cooled on ice for 2 hours. The formed crystals consisting of 2-(3,5-dimethoxy-4-hydroxybenzoyl)-isoxazolidine were collected by filtration and dried over phosphorus pentoxide. Yield 2.68 grams (78.1%), mp 75~76°C. Analysis:

Eksempel 6 Example 6

2-( 3, 5~ dimetoksy- 4- hydroksycinnamoyl)- isoxazolidin 2-( 3, 5~ dimethoxy- 4- hydroxycinnamoyl)- isoxazolidine

2,56 gram 2-(4-acetoksy-3,5-dimetoksycinnamoyl)-isoxazolidin ble suspendert i en blanding av 3,6 ml vann, 4 ml konsentrert ammoniakkoppløsning og 20 ml etanol. Suspensjonen ble holdt på 60°C i 2 timer, justert i varm tilstand til pH 7 og så avkjølt på is i 3 timer. Det dannede bunnfall som bestod av 2-(3,5-dimetoksy-4-hydroksycinnamoyl)-isoxazolidin ble oppsamlet og tørket som beskrevet ovenfor. Utbytte 2,1 gram (94,4%), smeltepunkt l66-l67°C. 2.56 grams of 2-(4-acetoxy-3,5-dimethoxycinnamoyl)-isoxazolidine was suspended in a mixture of 3.6 ml of water, 4 ml of concentrated ammonia solution and 20 ml of ethanol. The suspension was held at 60°C for 2 hours, adjusted while hot to pH 7 and then cooled on ice for 3 hours. The precipitate formed consisting of 2-(3,5-dimethoxy-4-hydroxycinnamoyl)-isoxazolidine was collected and dried as described above. Yield 2.1 grams (94.4%), melting point 166-167°C.

Analyse: Analysis:

Som nevnt ovenfor ble det nervøse utslag for de nye forbindelser indikert ved stangklatringsunngåelsesprøven på rotter. Denne prøve ble utført som beskrevet av Cook og V/eidley i Annals N. As mentioned above, the nervous response to the new compounds was indicated by the pole-climbing avoidance test in rats. This test was carried out as described by Cook and V/eidley in Annals N.

Y. Acad. Sei. 66 7^0 (1957 )., med noen modifikasjoner slik dette Y. Acad. Pollock. 66 7^0 (1957 )., with some modifications like this

er beskrevet av Maffii i J. Pharm. Pharmacol. 11 129 (1959)- is described by Maffii in J. Pharm. Pharmacol. 11 129 (1959)-

Apparatet består av en varme- og lydisolert boks utstyrt med en The device consists of a heat- and sound-insulated box equipped with a

rist av stålstaver som gulv, og disse er forbundet med en elektrisk stimulator. Boksen inneholder også en lydkilde, samt en trestand i midten som utgjør det trygge område. Rottene unngår de elektriske sjokk ved å klatre opp stangen. Etter at rottene er sluppet inn i boksen blir de underkastet følgende prøving: 15 sekunders stillhet, 15 sekunders akustisk stimulering, 30 sekunder av både elektrisk og akustisk stimulering. Når .dyret reagerer blir prøvingen avsluttet. Klatring på trestangen under den stille periode kalles CR^Csekunder betinget respons), klatring på stangen under den akustiske stimulering kalles CR^ (primær betinget respons) og klatring under den elektriske stimulering kall.es UR (ubetinget respons). tolkes som en nervøs reaksjon. grid of steel rods as a floor, and these are connected to an electrical stimulator. The box also contains a sound source, as well as a wooden stand in the middle which forms the safe area. The rats avoid the electric shocks by climbing the pole. After the rats are released into the box, they are subjected to the following test: 15 seconds of silence, 15 seconds of acoustic stimulation, 30 seconds of both electrical and acoustic stimulation. When the animal reacts, the test is terminated. Climbing the wooden pole during the silent period is called CR^Cseconds conditioned response), climbing the pole during the acoustic stimulation is called CR^ (primary conditioned response) and climbing during the electrical stimulation is called UR (unconditioned response). interpreted as a nervous reaction.

Manglen på .psykosedative, neurosedative og neurovegeta-tive effekter hos de nye forbindelser ble fastslått gjennom en observasjon av mus ifølge det prøveskjema 'som er angitt av Irwin, Gordon Res. Conf. Med. Chem., New London, N.M. 3-7/8, 133 (1959). The lack of psychosedative, neurosedative and neurovegetative effects in the new compounds was established through an observation of mice according to the test schedule set forth by Irwin, Gordon Res. Conf. With. Chem., New London, N.M. 3-7/8, 133 (1959).

Denne fremgangsmåte innbefatter at man systematisk observerer .grupper This procedure includes systematically observing groups

på 3 mus pr. dose, og hvor disse behandles méd økende doser av stoffet. De observerte forandringer blir så notert. of 3 mice per dose, and where these are treated with increasing doses of the substance. The observed changes are then noted.

Manglende effekt på arterietrykket ..ble målt i halspuls- Lack of effect on arterial pressure ..was measured in carotid pulse-

åren hos katter under, bedøvelse ved hjelp av natriumheksobarbital, vein in cats during, anesthesia with sodium hexobarbital,

'40 mg pr. kg intraper itonalt. Produktene ble injisert i den femurale arterie. En minimumssenkning på 20% i trykket i løpet av minst 20 minutter ble ansett som betydelig. '40 mg per kg intraper itonally. The products were injected into the femoral artery. A minimum reduction of 20% in pressure over at least 20 minutes was considered significant.

Resultatene i mg/kg for en del representative forbindelser The results in mg/kg for some representative compounds

er angitt i tabell I.- is indicated in table I.-

Claims (1)

Analogifremgangsmåte for fremstilling av terapeutisk aktive isoxazolidinderivater med den generelle formel:Analogous process for the preparation of therapeutically active isoxazolidine derivatives with the general formula: hvor n er 0 eller 1, og R^, R^ og R^ uavhengig representerer en hydroksy-, alkoksy- eller alkanoyioksygruppe med 1-4 karbonatomer, og hvor en av disse grupper kan være hydrogen, karakterisert ved at man omsetter isoxazolidin med en omtrent ekvi-molar mengde av et acylklorid med formelen:where n is 0 or 1, and R^, R^ and R^ independently represent a hydroxy, alkoxy or alkanoyioxy group with 1-4 carbon atoms, and where one of these groups can be hydrogen, characterized by reacting isoxazolidine with a approximately equimolar amount of an acyl chloride with the formula: hvor n har samme betydning som angitt ovenfor, og R^, R,- og Rg er alkoksy- eller alkanoyloksygrupper med 1-4 karbonatomer,og hvor en av disse grupper kan være hydrogen, i et oppløsningsmiddel i nærvær av en organisk nitrogenbase, og når en eller flere av substituentene i benzenringen er alkanoyloksygrupper, omdanner disse grupper til de tilsvarende hydroksygrupper ved alkalisk hydrolyse.where n has the same meaning as stated above, and R^, R,- and Rg are alkoxy or alkanoyloxy groups with 1-4 carbon atoms, and where one of these groups may be hydrogen, in a solvent in the presence of an organic nitrogen base, and when one or more of the substituents in the benzene ring are alkanoyloxy groups, these groups convert into the corresponding hydroxy groups by alkaline hydrolysis.
NO01242/70*[A 1969-04-24 1970-04-03 NO130400B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1600069 1969-04-24

Publications (1)

Publication Number Publication Date
NO130400B true NO130400B (en) 1974-08-26

Family

ID=11148429

Family Applications (1)

Application Number Title Priority Date Filing Date
NO01242/70*[A NO130400B (en) 1969-04-24 1970-04-03

Country Status (13)

Country Link
AT (1) AT296294B (en)
BE (1) BE748711A (en)
BR (1) BR6915476D0 (en)
CH (1) CH541570A (en)
DE (1) DE2019659A1 (en)
ES (1) ES378999A1 (en)
FI (1) FI49305C (en)
FR (1) FR2042369B1 (en)
GB (1) GB1243767A (en)
IL (1) IL34190A (en)
NL (1) NL146497B (en)
NO (1) NO130400B (en)
SE (1) SE349584B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853903A (en) * 1972-08-17 1974-12-10 Lepetit Spa Substituted 2 -benzoylisoxazolidines

Also Published As

Publication number Publication date
CH541570A (en) 1973-09-15
AT296294B (en) 1972-02-10
IL34190A0 (en) 1970-08-19
GB1243767A (en) 1971-08-25
NL146497B (en) 1975-07-15
FI49305C (en) 1975-05-12
BE748711A (en) 1970-09-16
IL34190A (en) 1974-03-14
FR2042369A1 (en) 1971-02-12
FI49305B (en) 1975-01-31
FR2042369B1 (en) 1973-06-08
ES378999A1 (en) 1973-01-16
BR6915476D0 (en) 1973-02-08
DE2019659A1 (en) 1970-10-29
SE349584B (en) 1972-10-02
NL7005470A (en) 1970-10-27

Similar Documents

Publication Publication Date Title
US3963729A (en) Pharmacologically active pyridine derivatives
US2831027A (en) Isocamphane compounds and processes for preparing the same
EP0007019A1 (en) 5-Phenyl-pyrazole derivatives and their salts, processes for their preparation and medicines containing them
EP0005231A2 (en) Isoquinoline derivatives, process for their preparation and pharmaceutical preparations containing them
EP0133530A2 (en) 1,6-Naphthyridinone derivatives, process for their preparation, and medicaments containing them
CH506525A (en) Aromatic ethers
SU722481A3 (en) Method of preparing aminoketone derivatives or their salts
US2503285A (en) Beta-substituted alpha, beta-diphenylethylamines and the preparation thereof
NO130400B (en)
NO300839B1 (en) New 2-cyano-3-hydroxy-propenamides and pharmaceutical preparations containing such
NO152786B (en) PROCEDURE FOR PREPARING 10,11-DIHYDRO-5H-DIBENZO- (A, D) -CYCLOHEPTEN-5,10-IMINES
NO149314B (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF PHYSIOLOGICALLY ACTIVE IMIDAZOISOKINOL INDIONS
NO155056B (en) EXPLOSIVES.
DD154487A5 (en) PROCESS FOR THE PREPARATION OF 1-BENZOXEPIN-5 (2H) -ONE DERIVATIVES
NO162017B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE ALFA-ARYL-ALFA-PYRIDYLALKANIC ACID DERIVATIVES.
US4013667A (en) 2,2-Diaryl-3-(1-azabicyclo[2.2.2]oct-2-yl)propionamides and intermediates thereto
CH637951A5 (en) 3-PYRAZOL-1-YL-PYRIDAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL PREPARATIONS CONTAINING THESE COMPOUNDS.
Shaw et al. Analogs of Aspergillic Acid. III. Synthesis of Cyclic Hydroxamic Acids with a Five-membered Ring
NO770014L (en) PROCEDURES FOR THE PREPARATION OF HYDROAZINE DERIVATIVES.
CH669196A5 (en) TRIAZOLOPYRIMIDINE AND METHOD FOR THE PRODUCTION THEREOF.
CH641457A5 (en) AZEPINO (1,2,3-LM) BETA CARBOLIN COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THE COMPOUNDS.
US3378592A (en) Process for the production of 3, 4-dihydroxybenzyloxyaminehydrobromide
DE2151487A1 (en) Pharmaceutical masses
EP0004322A1 (en) Isoquinolines, process for their preparation and their use for the preparation of medicines
SU1329620A3 (en) Method of producing isoquinoline or pharmaceutically acceptable additive acid salts thereof